The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Kodera
Honoraria - Ajinomoto; Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MSD K.K; Olympus; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - abbott Japan (Inst); Abbvie (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Japan Blood Products Organization (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Lilly Japan (Inst); Maruho (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst)
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization
 
Satoru Iwasa
Honoraria - Lilly Japan; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Wasaburo Koizumi
No Relationships to Disclose
 
Makio Gamoh
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo; Gilead Sciences; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Shionogi
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Ono Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)